Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway

被引:18
|
作者
Wang, Qi [1 ]
Wu, Hua [1 ]
Wu, Qingquan [1 ]
Zhong, Sheng [1 ,2 ]
机构
[1] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Thorac Surg, Huaian, Peoples R China
[2] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Thorac Surg, 1 Huanghe West Rd, Huaian 223000, Peoples R China
关键词
berberine; CCNE2; KIF20A; nonsmall cell lung cancer; PI3K/AKT pathway; IDENTIFICATION; EXPRESSION; SIGNATURE; THERAPY; GROWTH; POOR;
D O I
10.1002/ddr.22061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Nonsmall cell lung cancer (NSCLC) is the main type of lung cancer, accounting for approximately 85%. Berberine (BBR), a commonly used traditional Chinese medicine, has been reported to exhibit a potential antitumor effect in various cancers. In this research, we explored the function of BBR and its underlying mechanisms in the development of NSCLC.Methods: Cell Counting Kit-8 (CCK-8), 5-ethynyl-20-deoxyuridine (EdU), colony formation assays, flow cytometry, and transwell invasion assay were employed to determine cell growth, the apoptotic rate, cell invasion of NSCLC cells, respectively. Western blot was applied for detecting the protein expression of c-Myc, matrix metalloprotease 9 (MMP9), kinesin family member 20A (KIF20A), cyclin E2 (CCNE2), and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway-related proteins. Glycolysis was evaluated by detecting glucose consumption, lactate production, and adenosine triphosphate/adenosine diphosphate (ATP/ADP) ratio with the matched kits. Real-time quantitative polymerase chain reaction (RT-qPCR) was conducted to analyze the level of KIF20A and CCNE2. Tumor model was established to evaluate the function of BBR on tumor growth in NSCLC in vivo. In addition, immunohistochemistry assay was employed to detect the level of KIF20A, CCNE2, c-Myc, and MMP9 in mice tissues.Results: BBR exhibited suppressive effects on the progression of NSCLC, as evidenced by inhibiting cell growth, invasion, glycolysis, and facilitating cell apoptosis in H1299 and A549 cells. KIF20A and CCNE2 were upregulated in NSCLC tissues and cells. Moreover, BBR treatment significantly decreased the expression of KIF20A and CCNE2. KIF20A or CCNE2 downregulation could repress cell proliferation, invasion, glycolysis, and induce cell apoptosis in both H1299 and A549 cells. The inhibition effects of BBR treatment on cell proliferation, invasion, glycolysis, and promotion effect on cell apoptosis were rescued by KIF20A or CCNE2 overexpression in NSCLC cells. The inactivation of PI3K/AKT pathway caused by BBR treatment in H1299 and A549 cells was restored by KIF20A or CCNE2 upregulation. In vivo experiments also demonstrated that BBR treatment could repress tumor growth by regulating KIF20A and CCNE2 and inactivating the PI3K/AKT pathway.Conclusion: BBR treatment showed the suppressive impact on the progression of NSCLC by targeting KIF20A and CCNE2, thereby inhibiting the activation of the PI3K/AKT pathway.
引用
收藏
页码:907 / 921
页数:15
相关论文
共 50 条
  • [21] Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
    Zhao, Zhong-Quan
    Yu, Zhong-Yang
    Li, Jie
    Ouyang, Xue-Nong
    ONCOLOGY LETTERS, 2016, 12 (01) : 63 - 68
  • [22] Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway
    Liu, Chao
    Wang, Yun
    Dao, Yuyang
    Wang, Shuting
    Hou, Fei
    Yang, Zhixian
    Liu, Pengjie
    Lv, Juan
    Lv, Ling
    Li, Gaofeng
    Zhou, Youjun
    Deng, Zhiyong
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2022, 54 (01) : 99 - 112
  • [23] Plk3 Enhances Cisplatin Sensitivity of Nonsmall-Cell Lung Cancer Cells through Inhibition of the PI3K/AKT Pathway via Stabilizing PTEN
    Xu, Mengshan
    Deng, Xiaoyun
    Xiang, Nana
    Zhang, Zhao
    Yang, Min
    Liu, Qinxiang
    ACS OMEGA, 2024, 9 (08): : 8995 - 9002
  • [24] Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway
    Liu, Fujuan
    Liu, Tao
    Li, Haiying
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [25] Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway
    Fujuan Liu
    Tao Liu
    Haiying Li
    Cancer Cell International, 21
  • [26] MCAM modulates small cell lung cancer chemoresistance via PI3k/Akt/Sox2 signaling pathway
    Tripathi, Satyendra C.
    Fahrmann, Johannes F.
    Celiktas, Muge
    Aguilar, Mitzi
    Marini, Kieren D.
    Jolly, Mohit K.
    Katayama, Hiroyuki
    Wang, Hong
    Murage, Eunice N.
    Dennison, Jennifer B.
    Watkins, D. Neil
    Levine, Herbert
    Ostrin, Edwin J.
    Taguchi, Ayumu
    Hanash, Samir M.
    CANCER RESEARCH, 2017, 77
  • [27] CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway
    Xiao, Huan
    Zhang, Zhi'an
    Wei, Chunqing
    Peng, Dan
    Guo, Yuge
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2023, 44 (01) : 106 - 114
  • [28] PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway
    Wang, Shu
    Cheng, Zhiming
    Cui, Yan
    Xu, Shuoyan
    Luan, Qiu
    Jing, Shan
    Du, Bulin
    Li, Xuena
    Li, Yaming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [29] PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway
    Shu Wang
    Zhiming Cheng
    Yan Cui
    Shuoyan Xu
    Qiu Luan
    Shan Jing
    Bulin Du
    Xuena Li
    Yaming Li
    Journal of Translational Medicine, 21
  • [30] SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway
    Liu, Dajiang
    Yang, Yuan
    Yan, Aiqin
    Yang, Yongxiu
    ONCOTARGETS AND THERAPY, 2020, 13 : 351 - 359